Liver Diseases  >>  deleobuvir (BI 207127)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
deleobuvir (BI 207127) / Boehringer Ingelheim
NCT01830127 / 2012-003534-17: BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

Completed
2b
35
US, Europe
Ribavirin, BI 207127 high dose, Faldaprevir, BI 207127 low dose
Boehringer Ingelheim
Hepatitis C, Chronic
10/14
10/14
NCT01859962: Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

Checkmark EASL 2014
Mar 2014 - Mar 2014: EASL 2014
Checkmark HepDART 2013
Dec 2013 - Dec 2013: HepDART 2013
Checkmark AASLD 2013
More
Completed
2a
38
US
PPI-668, BI 207127 Dose 1, BI 207127 Dose 2, Faldaprevir, Ribavirin, BI 207127 Placebo
Presidio Pharmaceuticals, Inc., Boehringer Ingelheim
Chronic Hepatitis C
05/14
12/14
NCT01528735: This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

Completed
2
25
Japan
BI 207127 NA, peginterferon, Ribavirin, BI 201335 NA
Boehringer Ingelheim
Hepatitis C, Chronic
08/13
08/13
NCT01132313 / 2009-018197-66: Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

Checkmark SOUND-C3
Sep 2014 - Sep 2014: SOUND-C3
Checkmark EASL 2014
Mar 2014 - Mar 2014: EASL 2014
Checkmark APASL 2014: SOUND-C2 & SOUND-C3
More
Completed
2
488
US, Europe, RoW
BI 207127, BI 201335, Ribavirin, BI 207217
Boehringer Ingelheim
Hepatitis C, Chronic
10/14
10/14

Download Options